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Abstract
Soft tissue sarcomas are uncommon tumours of mesenchymal origin, most commonly arising in the extremities.
Treatment includes surgical resection in combination with radiotherapy. Resection margins are of paramount
importance in surgical treatment of soft tissue sarcomas but unambiguous guidelines for ideal margins of resection
are still missing as is an uniform guideline on the use of radiotherapy.
The present paper reviews the literature on soft tissue sarcomas of the extremities regarding the required resection
margins, the impact of new radiotherapy techniques and the timing of radiotherapy, more particularly if it should
be administered before or after surgical resection.
This review was started by searching guidelines in different databases (National Guideline Clearinghouse,
EBMPracticeNet, TRIP database, NCCN guidelines,…). After refinement of the query, more specific articles were
found using MEDLINE, PubMed, Web of Science and Google Scholar. Used keywords include “soft tissue sarcoma”;
“extremities OR limbs”; “radiotherapy”, “surgery”, “margins”, “local recurrence” and “overall survival”. Finally, the
articles were selected based on the accessibility of the full text, use of the English language and relevance based
on title and abstract.
Literature demonstrates positive resection margins to be an important adverse prognostic factor for local
recurrence of soft tissue sarcomas of the extremities. Still, no consensus is reached on the definition of what a good
margin might be. The evolution of new radiation techniques, especially Intensity Modulated Radiotherapy, resulted
in a s healthy surrounding tissues. However, the timing of radiotherapy treatment remains controversial as both
preoperative and postoperative radiotherapy are characterised by several advantages and disadvantages.
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Background
Soft tissue sarcomas (STS) are relatively uncommon
tumours, representing 1 % of adult and 7–15 % of paediat-
ric malignancies [1]. In Europe, the incidence is estimated
at 4-5/100.000/year [2]. It is a heterogeneous group of
tumours of mesenchymal origin that can occur anywhere
in the body, with the extremities being the most common
primary site, accounting for 60 % of the STS [3, 4]. More
than 50 different histological subtypes of STS have been
identified. Sarcomas are usually classified into two broad
categories: sarcomas of the soft tissues and sarcomas of
the bone. Furthermore, STS are subdivided in several
subgroups according to localization and treatment (e.g.
uterine, extremities, retroperitoneal, etc.) [3, 4]. This paper
will be dedicated to STS of the extremities (ESTS).
Up to three decades ago, sarcomas of the extremities
were frequently treated with amputation because of the
lack of an acceptable alternative concerning local control
rates. Advances in treatment, particularly the advent of
multimodality treatment, have lowered the amount of
amputations needed in the treatment of ESTS and have
favoured the use of limb-salvage techniques. In a subopti-
mal prospective randomized evaluation published in 1982,
Rosenberg et al. did not find any differences in overall
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survival rates or disease-free survival rates when compar-
ing limb-sparing surgery plus RT with amputation [5].
Two randomized series published in the Journal of Clin-
ical Oncology in the nineties proved the importance of
adjuvant RT as an important contributor in the success of
limb-sparing therapy [6, 7]. In a randomized prospective
study of Yang and colleagues postoperative external-beam
radiation therapy (EBRT) was shown to decrease the prob-
ability of local recurrence in a highly significant way with-
out influencing overall survival rates [6]. Despite several
radiation side effects, complaints were mostly transient
and few measurable negative effects on quality of Life
(QOL) were seen. Pisters et al. found similar results while
comparing surgery plus adjuvant brachytherapy with sur-
gery alone [7]. They found adjuvant brachytherapy to im-
prove local control after complete resection of STS. This
improvement in local control was limited to patients with
high-grade STS. A reduced occurrence of local recurrence
in patients with high-grade lesions was not associated with
a significant reduction in distant metastasis or improve-
ment in disease-specific survival.
Thus, combination of surgery and RT allows conserva-
tion of the limb and function without compromising dis-
ease control [4]. In 2003, Clarck et al. found the rate of
amputation to be already below 5 % in many oncological
centres for patients with primary limb or limb-girdle sar-
coma and 9–14 % for recurrent disease [8].
The use of new radiation techniques e.g. intensity modu-
lated radiotherapy (IMRT) has improved QOL and dose
localizations, increasing local control and disease-free
survival. At the same time a reduction in early and late
effects of RT including bone fractures, oedema and joint
stiffness was found [6, 9, 10]. The insight into the import-
ance of obtaining a good surgical margin has led to better
outcomes, especially for local control, as a positive surgical
margin appears to be the most important adverse factor
for local recurrence.
The role of chemotherapy in the treatment of STS is still
controversial. A meta-analysis by Pervaiz et al. showed only
a marginal efficacy with respect to local recurrence, distant
recurrence, overall recurrence and overall survival [11].
Patients with large, high grade STS who are at consider-
able risk for recurrence and metastasis, may benefit from
adjuvant chemotherapy [12]. A study of Mahmoud et al.
supports the use of neoadjuvant chemotherapy followed by
limb-sparing surgery and adjuvant RT for local failure re-
duction with a trend toward improved disease free survival
[13]. However, the role of chemotherapy in the curative set-
ting of high-risk STS remains debatable and its role unclear
in the absence of large randomized trials. The increased
toxicity and the possibly increased risk of secondary leukae-
mias also have to be taken into account when delivering
chemotherapy [14]. Because unequivocal proof of efficacy is
missing, systemic treatment will not be further discussed.
In this paper, the impact of the recent developments
in the treatment of ESTS will be studied. For surgery,
this includes the optimization of the resection margins.
For radiotherapy the focus will mainly be on the IMRT




Different studies have highlighted the importance of
adverse prognostic factors in the outcome of patients
with ESTS. Age (> 50 years), recurrent disease at presen-
tation and histologic subtypes (e.g. malignant peripheral-
nerve tumour) are important factors. But the single most
important factor seems to be a microscopically positive
margin (R1 resection) [15–18].
In this chapter the importance of surgical margins will
be discussed as well as the concept of what a good mar-
gin might/should be.
I. Surgical procedure
Surgery is the primary treatment for patients with ESTS
[18]. Performing surgery, the tumour can be resected with
different margins [3, 19]. A radical excision is the resec-
tion of a full compartment, a wide excision is an excision
of the tumour with a rim of normal tissue around it and a
marginal excision is one where the resection margins go
through the reactive zone (pseudo-capsule). This reactive
zone is a discoloured area around a tumour observable by
gross inspection, which is composed of haemorrhagic
tissue, scar tissue, degenerated muscle, oedema or tumour
capsule. Finally, an intralesional resection margin passes
through the tumour parenchyma [3, 19]. Kawaguchi et al.
define a curative margin as a margin of more than 5 cm
outside the reactive zone and a wide margin as a margin
of 4–1 cm [19]. Wide margins can be classified into two
subgroups: an adequate or an inadequate wide margin.
The former is defined as a margin of 2 cm or more and
the latter being a margin of 1–2 cm (see Fig. 1).
The standard surgical procedure is a wide excision with
negative margins (R0, no residual microscopic disease). To
guarantee an R0 resection the cutting face should go
through grossly normal tissue planes uncontaminated by
tumour. However, it is not always possible to obtain a nega-
tive margin and closer margins may be inevitable to pre-
serve critical neurovascular structures or bones. A marginal
excision may be acceptable as an individualized option in
carefully selected cases. Following the National Compre-
hensive Cancer Network (NCCN) Guideline 10 mm can be
accepted as an adequate margin [3]. A margin of less than
2 mm results in a marginal excision [2]. Because a positive
margin is a strong adverse predictor of local recurrence, re-
resection must be considered. In the case of R1 resections
(i.e. microscopic residual disease) re-resection is an option,
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but only if adequate margins can be achieved without major
morbidity, taking into account tumour extent and tumour
biology. In the case of R2 surgery (i.e. gross residual dis-
ease), re-resection in a reference centre is mandatory, pos-
sibly with preoperative treatments if adequate margins
cannot be achieved, or when surgery is thought to be muti-
lating. If re-resection is not possible or positive margins re-
main present after re-resection post-operative RT is
indicated [2, 3].
The NCCN guidelines also provide instructions on the
treatment of STS depending on tumour stage [3]. Using
the American Joint Committee on Cancer (AJCC) staging
system (see Table 1; [20]) the NCCN guidelines recom-
mend to proceed as follows:
Stage I Stage I STS should be treated with surgery to
obtain adequate surgical margins. If such margins can be
obtained or there is an intact fascial plane there is a suf-
ficient long-term local control. When appropriate mar-
gins cannot be obtained, RT needs to be considered.
However for stage IA tumours (< 5 cm) a wait and see
attitude can be adopted.
Stage II and III, resectable disease with acceptable
functional outcomes Stage IIA STS can be treated with
surgery only in case of small tumours when resection with
wide margins is possible, otherwise pre- or postoperative
radiotherapy can be delivered in addition to surgery.
In stage IIB or III tumours, surgery to obtain appropri-
ate surgical margins is combined with radiotherapy (pre-
or postoperatively).
Stage II and III, resectable disease with adverse
functional outcomes or unresectable primary disease
When the tumour cannot be resected with adequate
margins, radiotherapy should be given preoperatively to
downstage the tumour and to enable effective surgical
resection. When the mass becomes resectable it should
be resected to obtain appropriate surgical margins again
followed by RT. If the tumour remains unresectable the
further options are definitive RT, chemotherapy, pallia-
tive surgery, observation (if asymptomatic), sufficient
supportive care and amputation.
However, the question about the appropriate surgical mar-
gin for satisfactory local control remains unanswered so far.
II. Factors influencing choice of margin
The adequate minimal margin may depend on several
factors, including histological subtype, adjuvant therapies
and the presence of resistant anatomical barriers, such
as muscular fasciae, periosteum and epineurium [2–4].
Histological subtype The NCCN guidelines recom-
mend resection margins based on the malignancy grade
determined following the French Federation on Cancer
Centres Sarcoma Group (FNLCC) grading system [3, 21]
(see Table 2).
E.g., the cutaneous leiomyosarcoma is a primarily low-
grade malignancy. Deneve et al. concluded that good
oncological control and excellent outcomes are possible
with an only 1-cm resection margin in most cases [22].
This is in contrast with the treatment of the aggressive
cutaneous angiosarcoma consisting of surgical excision
Fig. 1 Surgical versus radiotherapeutic margins in the treatment of soft tissue sarcoma of the extremities Schematic description of margins used
in the therapy of ESTS. Margins used for radiotherapy differ from those used in surgical resection of the tumour. Nevertheless both include an
extra rim of healthy tissue as an attempt to include all microscopic disease around the vast tumour. CC = Cranio-caudal, CTV = clinical target
volume, GTV = gross tumour volume, LM = Latero-medial, RT = Radiotherapy
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with wide margins often combined with radiotherapy.
Moreover, in some cases even amputation remains un-
avoidable [23].
Adjuvant therapies Pre- and postoperative RT can in-
fluence surgical margins. As stated above the combin-
ation of surgery and RT allows conservation of the limb
and function without compromising disease control,
drastically lowering the need for amputation [4, 8].
RT biologically “sterilizes” microscopic extensions of
tumour thereby limiting the need for extensive margins,
consequently allowing sparing of critical organs and
neurovascular bundles [24]. Another possibly favourable
aspect of preoperative RT is the potential reduction of
the seeding of microscopic sarcomatous cells at the time
of surgical resection in addition to tumour shrinkage it-
self, which will greatly enhance the ability of the surgeon
to achieve negative margins [25].
Different aspects of RT in the treatment of ESTS will
be discussed later in this paper.
Resistant anatomical barriers The word ‘barrier’ refers
to any tissue that has resistance against tumour invasion,
and can include muscle fascia, joint capsule, tendon,
tendon sheath, epineurium, vascular sheath, cartilage,
pleura and peritoneum. Barriers can be classified as either
being a thick or a thin barrier. A thick barrier is a physic-
ally strong membranous tissue with a white tendinous
luster, e.g. an iliotibial band, a presacral fascia or a joint
capsule. The periosteum of an infant or young child can
also be included in this category. A thin barrier is a weaker
membranous tissue e.g. muscle fascia, the periosteum of
an adult, vessel sheath or epineurium [19].
Kawaguchi et al. tried to find a solution for the lack of in-
formation about an appropriate surgical margin in the sta-
ging system of Enneking [19, 26]. The surgical staging
system of Enneking is helpful in creating effective commu-
nication between different institutions all over the world
and provides a uniform language for comparison of treat-
ment [26]. However it does not solve the problem on how
to choose a good margin balancing between local control of
the lesion and maximum preservation of function. There-
fore, Kawaguchi et al. developed a modification of the sys-
tem of Enneking for better evaluation of the surgical
margins and for better refinement of limb salvage surgery
[19]. By considering barrier effects translated into concrete
distance equivalents, surgery can be done at sites where
barriers exist by using a smaller margin than true physical
Table 1 Definitions and Staging System of the American Joint Committee on Cancer, 7th Edition [74]
Primary tumour Regional Lymph Nodes Distant metastasis Gradea
Stage IA T1a N0 M0 G1, GX
T1b N0 M0 G1, GX
Stage IB T2a N0 M0 G1, GX
T2b N0 M0 G1, GX
Stage IIA T1a N0 M0 G2, G3
T1b N0 M0 G2, G3
Stage IIB T2a N0 M0 G2
T2b N0 M0 G2
Stage III T2a, T2b N0 M0 G3
Any T N1 M0 Any G
Stage IV Any T Any N M1 Any G
Primary Tumour (T)
TX, Primary tumour cannot be assessed
T0, No evidence of primary tumour
T1, Tumour 5 cm or less in greatest dimension*
-T1a, Superficial tumour
-T1b, Deep tumour
T2, Tumour larger than 5 cm in greatest dimension*
-T2a, Superficial tumour
-T2b, Deep tumour
*Note: Superficial tumour is located exclusively above the superficial fascia without invasion of the fascia; deep tumour is located either exclusively beneath the
superficial fascia, superficial to the fascia with invasion of or through the fascia, or both superficial to and beneath the fascia
Regional Lymph Nodes (N)
NX, Regional lymph nodes cannot be assessed
N0, No regional lymph node metastasis
N1**, Regional lymph node metastasis
**Note: Presence of positive nodes (N1) in M0 tumours is considered Stage III
Distant Metastasis (M)
M0, No distant metastasis
M1, Distant metastasis
aSee Table 2 for explanation FNCLCC grading system
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distance. It then becomes possible to choose a surgical plan
more safely. To clarify the minimal margin when barriers
exist, tumour excision with extremely small margins, which
nonetheless established local cure, were accumulated and
their barriers were considered to be the equivalent of 5 cm
thick healthy tissue. To convert these least safe margins
into a 5 cm equivalent distance, particular scores were
assigned to each type of barrier, with the final scores being
decided through several assessments of the patients.
Until now, conservative surgery with wide resection,
having 1 cm of normal tissue margin or intact anatomical
barriers, such as muscular fascia or periosteum, is the
most commonly performed procedure [27]. The European
Society for Medical Oncology (ESMO) guidelines also
tried to define the anatomical structures that could be
used as good barriers for surgery [2]. They concluded that
muscular fascia, periosteum and epineurium are resistant
anatomical barriers.
Therefore, in the presence of an anatomical structure
functioning as a resistant barrier for tumour growth,
smaller resection margins can be acceptable [2, 19, 27, 28].
III. Impact of surgical margin on outcome
Local control There is strong evidence that a positive
surgical margin is a strong predictor of local recurrence
for patients with ESTS. The status of the surgical margin
is the factor having the most profound effect on local re-
currence as reported consistently in literature [16, 28–31].
In a prospective study of 1041 patients with ESTS Pis-
ters et al. found a microscopically positive surgical mar-
gin to be a significant adverse prognostic factor for local
recurrence [15]. Of the 1041 patients that were followed
242 (23 %) had a positive surgical margin. Of these, 64
(26 %) developed local recurrence. The study of Pister et
al. was also the first study to suggest that there is a rela-
tionship between positive margins and tumour-related
mortality. They found that the adverse prognostic factors
for local recurrence in ESTS were different from those
that predict distant metastasis and disease free survival.
This has a clinical implication because staging systems
to stratify patients for risks of distant metastasis and
tumour-related mortality using these prognostic factors
will not stratify patients for local recurrence.
Many years later, in 2012 David J. Biau et al. performed a
similar study [32]. In their cohort of 1668 patients with a
STS of the extremity or trunk patients with positive surgical
margins had a 3.3 times greater risk of developing a local re-
currence compared with those who had negative surgical
margins.
Distant recurrence and metastasis A lot of uncertain-
ties remain on the impact of surgical margins on distant
metastasis. It is most likely that the surgical margins do
not have a direct influence on distant metastasis. Local
recurrence is associated with an increased risk of metas-
tasis but an inadequate surgical margin is not a risk
factor for metastasis. The study of Trovik et al. confirms,
in regard to metastasis, tumour-related risk factors
(malignancy grade and tumour size) to be much more
important than treatment-related risk factors like surgi-
cal margins [16]. Local recurrence was associated with
an increased metastasis rate, whereas inadequate surgical
margin was a risk factor for local recurrence but not for
metastasis. Other studies came to the same conclusions
[33–35]. Deep seated lesions, tumour size > 10 cm, high-
grade and recurrence after radical surgery are all found
to be high risks factors for distant metastasis [31].
Overall survival The effect of surgical margin and local
recurrence on overall survival is a well-discussed issue in
literature as local recurrence is a significant factor asso-
ciated with decreased survival [17, 35, 36]. Patients with
positive surgical margins, putting them at high risk for
local failure, should be considered for increased surveil-
lance, as local failure is associated with subsequent
metastasis and decreased survival [35]. This association
between local failure and decreased survival makes it
very important to achieve negative resection margins in
STS. If this is not achieved after primary treatment a re-
excision is recommended. Lack of re-excision after local




Score 1 Sarcoma closely resembling normal
adult mesenchymal tissue
(e.g., well-differentiated liposarcoma)
Score 2 Sarcomas for which histologic typing
is certain (e.g. myxoid liposarcoma)
Score 3 Embryonal and undifferentiated
sarcomas; sarcomas of uncertain type
Mitosis Count
Score 1 0-9/10 HPF
Score 2 10-19/10 HPF
Score 3 ≥20/10 HPF
Tumour Necrosis (Microscopic)
Score 0 No necrosis
Score 1 ≤50 % tumour necrosis
Score 2 >50 % tumour necrosis
Histologic Grade
Grade 1 Total score 2,3
Grade 2 Total score 4,5
Grade 3 Total score 6,7,8
FNCLCC Fédération Nationale de Centres de Lutte Contre le Cancer, HPF
high-power field
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failure has proven to be associated with a decreased
overall survival and an increased risk of metastasis as
found in the study of Zagars et al. [37].
Newer evidence found unplanned resection at a non-
referral hospital to be the most important risk factor for
overall survival because of the high rates of inappropri-
ate margins achieved in those cases. Accurate diagnosis
and adequate initial surgery are the most important fac-
tors for improving clinical outcomes.
Treatment in specialized sarcoma centres is therefore
crucial and can be life-saving [38].
In conclusion, the importance of good surgical mar-
gins after surgery of ESTS in achieving local control has
been proven in different studies [31, 39–41]. However
the relationship between surgical margins and distant
metastasis remains unclear [16].
Inadequate surgical margins, local recurrence and me-
tastasis are all significantly associated with decreased over-
all survival [30]. However, although appropriate margins
are associated with a better prognosis, there still is no gen-
eral agreement on the definition of the ideal margin [24].
Radiotherapy
Radiotherapy is an essential adjunct to surgery for adult
soft-tissue sarcomas in optimizing both local control and
functional outcome [42]. According to the NCCN guide-
lines RT should always be implemented in the therapy of
STS in stage II or III disease [3]. In stage I STS RT can
be considered when resection margins are less than
1 cm in the absence of intact fascial planes. RT can be
applied neoadjuvant (preoperative) or adjuvant (postop-
erative) to surgery. The advantages and disadvantages of
both approaches will be discussed later in this paper.
Exceptionally, radiotherapy can also be administered as
a primary local therapy when general health is too poor
to undergo surgery or when the sarcoma cannot be cu-
ratively removed e.g. when it has already spread [9, 43].
Outcomes in patients with STS have improved with new
developments in RT technology such as IMRT and intra-
operative radiation therapy (IORT) [9].
Despite its proven efficacy a recent article of Bagaria et al.
reports an underuse of RT for a significant amount of STS
patients in the US [44]. More effort needs to be directed
towards compliance since only 60 % of the stage II and III
tumours underwent RT whereas 25 % of the stage I tu-
mours did, even though not recommended for this group.
This section will give a brief overview of the different
RT-techniques.
I. Types of radiation therapy
External radiation External radiation is the most com-
monly used form of RT [43]. A very important evolution
in external beam RT is the development of intensity
modulated RT (IMRT) since the late nineties. The main
advantage of this technique is its sharp dose gradients
enabling very precise irradiation of the target volumes,
thereby minimizing the high dose radiation to the sur-
rounding healthy tissues [45]. This makes IMRT espe-
cially suitable for treating complex treatment volumes
minimizing dose to organs at risk (OAR) nearby, that
otherwise might necessitate dose limitations [42].
The past two decades, IMRT became a standard tech-
nique despite its drawbacks of volume delineation, plan-
ning, robustness of delivery, challenging quality assurance
and cost as compared with non-IMRT. Theoretically, the
advantages of IMRT over non-IMRT are well accepted but
insufficient evidence is available to conclude for the
clinical setting. The main incentive to choose IMRT over
non-IMRT is its capacity to reduce toxicity. Findings re-
garding survival, tumour control or other indexes of treat-
ment efficacy remain generally inconclusive. Comparative
case series show no differences in disease control and sur-
vival unless dose escalation was used [46].
In the study of Alektiar and colleagues, the low risk of
complications was confirmed [10]. Even in a population at
high risk for bone fractures only 4,8 % actually developed
a fracture. To treat these fractures, no surgical interven-
tion was required, which is unusual with RT-associated
bone fractures. Other complications such as oedema and
joint stiffness also decreased when compared with con-
ventional RT. Despite the excellent results of adjuvant
IMRT for primary ESTS in this study, more investigations
are needed to confirm the data on a larger number of pa-
tients and with a longer period of follow-up.
In 2013 two prospective phase II studies, which com-
pared IMRT with classical RT in its rate of normal tissue
morbidity, have been published. O’Sullivan et al. found a
numerical reduction in wound complications while using
preoperative image-guided IMRT compared to classical
RT [47]. This reduction in wound complications however,
did not reach statistical significance, but it did significantly
diminish the need for tissue transfer. Chronic RT morbid-
ities and the need for subsequent secondary operations for
wound complications were lowered, although not signifi-
cantly, whereas good limb function was maintained. Wang
and colleagues, on the other hand, showed IMRT to sig-
nificantly reduce the RT related late morbidities as fibro-
sis, oedema and joint stiffness [48]. IMRT provided
excellent local control for patients with STS of the
extremities and trunk. In a recent study, Folkert et al. even
showed a significant reduction in local recurrences when
comparing IMRT and conventional RT in treatment of
primary ESTS [49]. In this single institution study 319 pa-
tients with primary ESTS were treated using limb-sparing
surgery and adjuvant RT, 154 patients using classical ex-
ternal beam RT and 165 patients using IMRT. On multi-
variable analysis adjusting for patient age and tumour size,
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IMRT retained significance as an independent predictor
of reduced local recurrence.
A possible concern about IMRT is that its tight dose
distribution, an advantage in reducing RT morbidity to sur-
rounding normal structures, might compromise tumour
coverage. However, Alektiar and colleagues showed, in a
group of high-risk patients, IMRT to contribute to an
excellent local control [10]. In some instances the tumour
coverage may even be improved using IMRT. For example
with large thigh sarcomas, the limb contour near the groin
is significantly different from the contour near the knee,
leading to underdosage, with a potential local relapse, in
the former and overdosage, a potential for toxicity, in the
latter in the case of conventional RT. This is no longer a
problem when using IMRT.
Moreover, recently detailed guidelines for RT target
volume delineation have been published by the Radiation
Therapy Oncology Group (RTOG; preoperative RT) and by
Haas and his European, American and Canadian colleagues
(pre- and postoperative RT) [50, 51].
For preoperative RT of primary large high-grade ESTS
the gross tumour volume (GTV), being the volume of
known infiltration, is defined by T1 contrast-enhanced
magnetic resonance images according to the RTOG [50].
The clinical target volume (CTV), being the volume of
suspected (microscopic) infiltration, is defined as the
GTV plus 3 cm margins in the longitudinal directions,
limited to the compartment. The radial margin from the
lesion should be 1–1.5 cm if not confined by intact
fascial barrier, bone or skin surface. This CTV should be
manually edited to encompass any suspicious oedema
on MRI T2 images. Haas & al. confirm these definitions
except for the CTV in the longitudinal direction, which
is defined as the GTV plus 4 cm margins, limited to the
compartment [51]. A dose of 50 Gy in 25 fractions
should be administered to this target volume [3, 51, 52]
(See Fig. 1). In function of the resection margins, an
additional ‘boost’ dose of 16–26 Gy to the high-risk zone
can be indicated (see post-operative RT).
Therewithal they published guidelines for RT target vol-
ume delineation in postoperative RT. The GTV cannot be
defined after removal of the tumour but the original
tumour extensions should be recreated within the plan-
ning CT data set. The first a portion of the dose (45–
50.4 Gy) is applied to a larger volume encompassing the
surgical bed with appropriately safety margins, called the
elective CTV. This is followed by supplementary dose
(16–26 Gy) to a smaller ‘boost’ CTV [3, 51]. The elective
CTV is defined as the reconstructed initial tumour volume
surrounded by the same margins as used for preoperative
RT. However, this volume might have to be adjusted for it
needs to include all visible clips, drain sites, the entire
length of the scar and the entire extent of the operative
field. The boost CTV is the same volume as the elective
CTV, except in the longitudinal direction, where it is de-
fined by the reconstructed GTV plus only a 2 cm margin.
Intraoperative radiation therapy (IORT) IORT is one
of the advances in therapy of STS. One large dose of radi-
ation is administered during surgery, after resection but
before stitching the wound. Hereby the operative field can
be irradiated directly and the healthy tissues can be spared.
This type of RT is often combined with postoperative RT
[43]. IORT is mainly used in treatment of STS in the pelvis
or abdomen, its use in peripheral tumours is limited al-
though a study of Tran et al. in 2006 showed that IORT
used as a boost to EBRT provides excellent local control,
with limited acute toxicities when used in treating ESTS
[4]. These findings were confirmed in a recent study of Call
et al. on upper-extremity STS where treatment including
IORT was associated with excellent local control, limb
preservation and survival [53].
Brachytherapy Sometimes called internal radiation
therapy, brachytherapy involves the direct application of
radioactive sources into the tumour bed through cathe-
ters placed during surgery. With a fast decay of the dose
by the distance, these sources are able to deliver a highly
concentrated radiation dose more conformal compared
to external beam RT, resulting in improvement in local
control together with better sparing of the surrounding
healthy tissues. Two different types of brachytherapy can
be distinguished: high-dose rate (HDR) brachytherapy
and low-dose rate (LDR) brachytherapy. In HDR brachy-
therapy, a great amount of radiation is emitted over a
short period of time and the sources stay in place for
only a few minutes. For the LDR technique the sources
may stay in place for several days [43]. LDR and HDR
brachytherapy are associated with similar rates of local
control. It has been suggested that HDR brachytherapy
may be associated with lower incidences of severe tox-
icity. However, this has not been proven in randomized
clinical trials [3, 54]. Pulsed Dose Rate (PDR) brachy-
therapy is a relatively new RT modality. It uses stronger
radiation sources compared to LDR brachytherapy but
simulates its total dose by providing pulses of 10 to
30 minutes long exposures every hour. It thereby com-
bines physical advantages of HDR technology with
radiobiological advantages of LDR brachytherapy [55].
Brachytherapy is mostly administered as a boost that
is supplemented with EBRT, but it can also be an attract-
ive alternative to EBRT as a form of adjuvant RT. The
period of treatment is much shorter, the financial costs
are lower, evaluation at the time of surgery is possible
and by sparing the surrounding tissues needless compli-
cations can be averted [56, 57]. However, brachytherapy
techniques require special expertise and experience,
restricting its availability.
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Hadron therapy With hadron therapy charged particles
(protons and other ions such as carbon) are used to
irradiate the tumour. A recent advancement in therapy
of STS is Proton-Beam RT where a beam of protons irra-
diates the tumour. Compared to photons (e.g. x-rays),
protons allow a superior dose distribution because pro-
tons depose little energy in tissue until near the end of
the proton range where the residual energy is deposed
over a short distance resulting in a steep peak in the
absorbed dose known as the Bragg peak. Despite this
advantage it has not been proven to be a better treat-
ment in STS patients and its availability is limited [9,
43]. Heavy-ion therapy is the use of particles more
massive than protons or neutrons, such as carbon ions.
Compared to protons, carbon ions are correlated with a
higher density of ionization at the end of their range in-
creasing the biological efficiency of the dose and making
them less dependent of oxygen and therefore interesting
in the treatment of radioresistant and hypoxic tumours.
Notwithstanding this advantage, the costs of this form of
RT are very high restricting its availability to less than
ten facilities worldwide [58].
In conclusion, advances in radiotherapy techniques di-
minish normal tissue complications because of their
dosimetric advantages compared to conventional RT and
might result in higher local control rates.
II. Timing
There is still a lot of debate whether RT should be given
before or after surgery and what the best interval be-
tween surgery and RT can/should be? A tendency arises
to choose for the preoperative technique. In the USA
this type of RT is predominant over the post-operative
form. In Europe the post-operative type remains the
mainstream. Next, an overview of the primordial advan-
tages and disadvantages of both techniques will be given.
Preoperative versus Postoperative RT (see Table 3)
Preoperative RT
Preoperative RT has several advantages. First, the
treatment volume can be smaller because there is no
need to cover the entire operative field, resulting in a
lower integral dose. The use of preoperative RT can
thereby reduce the risk for late complications [59]. In a
study of Nielsen et al., the field size used for preopera-
tive irradiation was compared with the field size needed
to treat that same patient postoperatively [60]. Preopera-
tively a radial margin of 5 cm around the tumour was
used for low and intermediate grade and 7 cm for high-
grade sarcomas. The same margins were used to treat
the tumour postoperatively but now around the surgical
field. Independently of surgical procedure and tumour
grade, the size of the preoperative radiation field and the
number of joints included in the field were significantly
smaller than in the postoperative radiation setting.
Stated that the rate of complications is proportional to
the magnitude of the radiated area and when the same
radiation parameters regarding time, dose and fraction
are used, a lower incidence of late complications may be
expected with preoperative RT [59, 60].
Furthermore, resection of a tumour can become easier
after administration of preoperative RT. The tumour
may or may not regress with preoperative RT, but the
pseudocapsule may thicken and become acellular, easing
resection and decreasing the risk of recurrence [3]. At
last, by applying RT before surgery, better oxygenation
and vascularization of the area ensures a greater effect of
RT, permitting a lower total dose to be administered,
resulting in a better functional outcome.
However, preoperative RT has also several disadvan-
tages. The main disadvantage is the frequent occurrence
of major wound complications, especially in the lower
limbs. These complications can have a detrimental effect
on the function of STS patients [61, 62]. In a randomized
trial, O’Sullivan et al. compared the appearance of wound
complications in preoperative and postoperative RT [59].
The primary endpoint was rate of wound complications
within 120 days of surgery. Wound complications were re-
corded in 35 % and 17 % of the preoperative and postop-
erative group, respectively. Overall survival was slightly
better in patients who received preoperative RT. Another
important disadvantage is the delay in surgery. After RT,
an interval of 3–6 weeks is required to decrease the risk of
wound complications and to cool down the acute reac-
tions. Nevertheless, it is not recommended either to create
an interval that is too long because this can lead to the de-
velopment of late fibrosis which can hamper surgery [3].
However, through the advances in RT mentioned above,
this inconvenient side effect has been reduced by avoiding
high dose radiation on the healthy surrounding tissues.
If a wide resection is possible, additional RT may be re-
dundant. However if the tumour is located nearby a neu-
rovascular bundle or next to bony structures, close
margins may be unavoidable. In this case a postoperative
RT boost with brachytherapy, IORT or EBRT is recom-
mended [63]. The usual dose of preoperative RT is 50 Gy.
For the postoperative boost different dose levels exist. The
NCCN guidelines recommend doses of 10–14 Gy for
close margins, 16–20 Gy for microscopically positive mar-
gins (R1), and 20–26 Gy for grossly positive margins (R2)
[3]. However, some data suggest that some patients with
positive margins following preoperative RT and surgery
may do well without a boost [64, 65]. Ali Al Yami et al.,
found no difference in local control comparing patients
with a margin-positive excision who received preoperative
RT alone with patients who received preoperative RT and
a postoperative boost [64]. Moreover, higher radiation
doses contain a greater risk for late complications such as
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fractures, fibrosis, oedema and joint stiffness. The recent
study of Alamanda et al. confirmed these findings [65]. No
differences in rates of local recurrence, distant metastasis
or death due to STS were found in patients who received
a postoperative boost versus those who did not.
Postoperative RT
To eliminate any cancer cells that may remain after
surgery, RT can be given postoperatively as an adjuvant
therapy. Also postoperative RT is characterized by sev-
eral advantages and disadvantages.
When a tumour is resected before radiotherapy, better
staging of the tumour is possible. The amount of scar com-
plications is also lower. The number of late complications,
on the other hand, rises. A study of Davis and colleagues
showed significantly more late fibrosis in postoperative RT
compared to preoperative RT [66]. Although not statisti-
cally significant, the percentage of patients with late
oedema and joint stiffness was also higher in the postopera-
tive group. The higher rate of late complications compared
to preoperative RT may be due to the higher total radiation
dose, 50 Gy preoperatively (no boost necessary when nega-
tive margins are reached) compared to 60–66 Gy in post-
operative RT, and the larger area that needs to be irradiated
[3]. A last possible difficulty concerning postoperative RT
lies in the need for optimal cooperation between radio-
therapist and surgeon. The surgeon plays a major role in
the RT success rate by marking the operation field with
clips to indicate the area that needs to be irradiated.
After surgery RT can be administered intra-operatively,
with brachytherapy or by EB RT. Most of the times the
entire surgical site is included. The total dose should al-
ways be determined by the tolerance of the healthy tissues.
According to the NCCN guidelines, a boost of 16–18 Gy
should be given if microscopical residual tumour (R1) is
left behind. In case of gross residual disease (R2), a boost
of 20–26 Gy is indicated [3]. Decisions regarding the use
of postoperative RT should always be individualized and
should not only be based on positive or negative resection
margins as described above. Histological grade, age of
the patient, localisation of the tumour including vicinity
of neurovascular structures etc. should be taken into
account.
Adjuvant RT has been shown to improve local control
in ESTS. Alektiar et al. showed adjuvant RT to improve
local control in patients with high-grade ESTS with posi-
tive margins [67]. In a more recent report of 2008 Jebsen
and colleagues also showed that adjuvant RT effectively
prevents local recurrences in STS, irrespective of the
tumour depth, malignancy grade and surgical margin
status [68].
According to a paper of the International Journal of
Radiation Oncology, the interval between surgery and
postoperative RT does not significantly impact the 10-
year local control rate [69]. Hence, a RT delay should
not be viewed as an independent adverse factor for local
control and therefore it should not be compensated with
increased doses RT.
Regardless of all the differences in advantages and dis-
advantages in the use of preoperative or postoperative
RT, multiple studies did not find evidence for differences
in disease outcome [59, 70–73].
Conclusions
In the last decades, multi-modality treatment has im-
proved functional outcome of ESTS. However, a lot of
questions remain.
Regarding surgery, the importance of surgical resection
margins can no longer be underestimated. Literature has
reached consensus on the adverse effect of positive re-
section margins on local control of STS. Positive mar-
gins and local recurrence also seem to have an
important influence on overall survival. However the
concept of an ideal surgical margin remains unclear.
There is a high need for standardisation and guidelines
concerning good surgical margins for ESTS resection.
Radiotherapy improves local control of ESTS com-
pared with surgery alone. New techniques as IMRT and
IORT, although technically challenging, are implemented
in the treatment of STS because of their dosimetric
advantages compared to conventional RT. Healthy tis-
sues are spared and the amount of normal tissue compli-
cations diminishes. Especially the introduction of IMRT
in the last 20 years has resulted in an important decrease
in toxicity. Pre- and postoperative RT each have their
own advantages and disadvantages. It is, however, not
clear which RT sequence is superior.
For surgery as well as radiotherapy, further research is
necessary and urgent.
Table 3 Advantages and disadvantages of pre- and postoperative radiotherapy
Advantages Disadvantages
Preoperative Radiotherapy • Smaller RT volume
• Easier resection
• Better oxygenations and vascularization
of the area = > larger effect
• Reduction of late complications
• Wound complications
• Postponing surgery
• Fibrosis that could hamper surgery
Postoperative Radiotherapy • Better staging
• Less scar complications
• Large RT Volumes
• More late complications (fibrosis, joint stiffness, oedema)
• Need for demarcation of the operation field (clips)
Hoefkens et al. Radiation Oncology  (2016) 11:136 Page 9 of 12
Abbreviations
AJCC: American Joint Committee on Cancer; CT: Computed tomography;
CTV: Clinical target volume; EBRT: External beam radiation therapy;
ESMO: European Society for Medical Oncology; ESTS: Extremity soft tissue
sarcomas; FNLCC: French Federation on Cancer Centres Sarcoma Group;
GTV: Gross tumour volume; Gy: Gray; HDR: High dose rate; IMRT: Intensity
modulated radiotherapy; IORT: Intraoperative radiation therapy; LDR: Low
dose rate; NCCN: National comprehensive cancer network; OAR: Organs at
risk; PDR: Pulsed dose rate; QOL: Quality of life; RT: Radiotherapy;
RTOG: Radiation Therapy Oncology Group; STS: Soft tissue sarcomas
Acknowledgements
The authors wish to thank Felix Shumelinsky from the Jules Bordet Institute
for his critical review of the article
Funding
Not applicable.
Availability of data and materials
Not applicable.
Authors’ contributions
FH and CD participated in the study design, revised and analyzed literature,
interpreted data and drafted the manuscript. JS participated in the study
design, interpreted data, helped draft the surgery part of the manuscript and
revised the total manuscript critically. PM interpreted data and revised the
manuscript critically. DVG participated in the study design and was
responsible for the study coordination, interpreted data, helped draft the
radiotherapy part of manuscript and revised the total manuscript critically.
All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Not applicable.
Author details
1Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp,
Belgium. 2Department of Orthopaedic Surgery, Antwerp University Hospital,
Edegem, Belgium. 3Department of Radiotherapy, University Radiotherapy
Antwerp UZA/ZNA, Antwerp, Belgium. 4Department of Radiotherapy, Institut
Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Received: 14 December 2015 Accepted: 13 July 2016
References
1. Morrison BA. Soft tissue sarcomas of the extremities. Proceedings. 2003;
16(3):285–90. Pubmed Central PMCID: 1200782.
2. Group EESNW. Soft tissue and visceral sarcomas: ESMO Clinical Practice
Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23
Suppl 7:vii92–9.
3. von Mehren M, Lor Randall R, DeLaney T, George S, Riedel R, Scheutze S, et
al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Soft
Tissue Sarcoma. 2014;2.2014:126.
4. Tran QN, Kim AC, Gottschalk AR, Wara WM, Phillips TL, O'Donnell RJ, et al. Clinical
outcomes of intraoperative radiation therapy for extremity sarcomas. Sarcoma.
2006;2006(1):91671. Pubmed Central PMCID: 1557794, Epub 2006/10/17.
5. Rosenberg SA, Tepper J, Glatstein E, Costa J, Baker A, Brennan M, et al. The
treatment of soft-tissue sarcomas of the extremities: prospective randomized
evaluations of (1) limb-sparing surgery plus radiation therapy compared with
amputation and (2) the role of adjuvant chemotherapy. Ann Surg. 1982;196(3):
305–15. Pubmed Central PMCID: 1352604, Epub 1982/09/01.
6. Yang JC, Chang AE, Baker AR, Sindelar WF, Danforth DN, Topalian SL, et al.
Randomized prospective study of the benefit of adjuvant radiation therapy
in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol. 1998;
16(1):197–203. Epub 1998/01/24.
7. Pisters PW, Harrison LB, Leung DH, Woodruff JM, Casper ES, Brennan MF.
Long-term results of a prospective randomized trial of adjuvant
brachytherapy in soft tissue sarcoma. J Clin Oncol. 1996;14(3):859–68.
8. Clark MA, Thomas JM. Amputation for soft-tissue sarcoma. Lancet Oncol.
2003;4(6):335–42.
9. DeLaney TF, Trofimov AV, Engelsman M, Suit HD. Advanced-technology
radiation therapy in the management of bone and soft tissue sarcomas.
Cancer Control. 2005;12(1):27–35. Epub 2005/01/26.
10. Alektiar KM, Brennan MF, Healey JH, Singer S. Impact of intensity-modulated
radiation therapy on local control in primary soft-tissue sarcoma of the
extremity. J Clin Oncol. 2008;26(20):3440–4. Epub 2008/07/10.
11. Pervaiz N, Colterjohn N, Farrokhyar F, Tozer R, Figueredo A, Ghert M. A
systematic meta-analysis of randomized controlled trials of adjuvant
chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008;
113(3):573–81.
12. Look Hong NJ, Hornicek FJ, Harmon DC, Choy E, Chen YL, Yoon SS, et al.
Neoadjuvant chemoradiotherapy for patients with high-risk extremity and
truncal sarcomas: a 10-year single institution retrospective study. Eur J
Cancer. 2013;49(4):875–83. Pubmed Central PMCID: 3777719.
13. Mahmoud O, Dosch A, Kwon D, Pitcher JD, Conway S, Benedetto P, et al.
The impact of perioperative chemotherapy timing in conjunction with
postoperative external-beam radiation therapy on extremity soft-tissue
sarcomas outcome. Am J Clin Oncol. 2014.
14. Schmitt T, Lehner B, Kasper B, Bischof M, Roeder F, Dietrich S, et al. A phase
II study evaluating neo-/adjuvant EIA chemotherapy, surgical resection and
radiotherapy in high-risk soft tissue sarcoma. BMC Cancer. 2011;11:510.
Pubmed Central PMCID: 3248452.
15. Pisters PW, Leung DH, Woodruff J, Shi W, Brennan MF. Analysis of
prognostic factors in 1,041 patients with localized soft tissue sarcomas of
the extremities. J Clin Oncol. 1996;14(5):1679–89.
16. Trovik CS, Bauer HC, Alvegard TA, Anderson H, Blomqvist C, Berlin O, et al.
Surgical margins, local recurrence and metastasis in soft tissue sarcomas:
559 surgically-treated patients from the Scandinavian Sarcoma Group
Register. Eur J Cancer. 2000;36(6):710–6.
17. Eilber FC, Rosen G, Nelson SD, Selch M, Dorey F, Eckardt J, et al. High-grade
extremity soft tissue sarcomas: factors predictive of local recurrence and its
effect on morbidity and mortality. Ann Surg. 2003;237(2):218–26. Pubmed
Central PMCID: 1522131.
18. Chao AH, Mayerson JL, Chandawarkar R, Scharschmidt TJ. Surgical management
of soft tissue sarcomas: Extremity sarcomas. J Surg Oncol. 2014;111(5):540–5.
19. Kawaguchi N, Ahmed AR, Matsumoto S, Manabe J, Matsushita Y. The
concept of curative margin in surgery for bone and soft tissue sarcoma. Clin
Orthop Relat Res. 2004;419:165–72.
20. Goldblum RJ, Folpe AL, Weiss SW. Enzinger and Weiss’s soft tissue tumors.
6th ed. Philadelphia: Elsevier Saunders; 2013.
21. Coindre JM. Grading of soft tissue sarcomas: review and update. Arch
Pathol Lab Med. 2006;130(10):1448–53.
22. Deneve JL, Messina JL, Bui MM, Marzban SS, Letson GD, Cheong D, et al.
Cutaneous leiomyosarcoma: treatment and outcomes with a standardized
margin of resection. Cancer Control. 2013;20(4):307–12.
23. Le Corre Y, Avenel-Audran M, Croue A, Steff M, Verret JL. Cutaneous
angiosarcoma of the leg without lymphoedema. Ann Dermatol Venereol. 2008;
135(6–7):488–91. Angiosarcome cutane de jambe sans lymphoedeme associe.
24. Kandel R, Coakley N, Werier J, Engel J, Ghert M, Verma S, et al. Surgical margins
and handling of soft-tissue sarcoma in extremities: a clinical practice guideline.
Curr Oncol. 2013;20(3):e247–54. Pubmed Central PMCID: 3671031.
25. Wolfson AH. Preoperative vs postoperative radiation therapy for extremity
soft tissue sarcoma: controversy and present management. Curr Opin
Oncol. 2005;17(4):357–60.
26. Simon MS, Springfield DS. Surgery for bone and soft-tissue tumors:
Lippincott Williams & Wilkins; 1997.
27. Garcia del Muro Solans X, Martin Broto J, Lianes Barragan P, Cubedo Cervera R,
SEOM. SEOM clinical guidelines for the management of adult soft tissue
sarcomas. Clin Transl Oncol. 2012;14(7):541–4.
28. Sampo M, Tarkkanen M, Huuhtanen R, Tukiainen E, Bohling T, Blomqvist C.
Impact of the smallest surgical margin on local control in soft tissue
sarcoma. Br J Surg. 2008;95(2):237–43.
29. Stojadinovic A, Leung DH, Hoos A, Jaques DP, Lewis JJ, Brennan MF.
Analysis of the prognostic significance of microscopic margins in 2,084
localized primary adult soft tissue sarcomas. Ann Surg. 2002;235(3):424–34.
Pubmed Central PMCID: 1422449.
Hoefkens et al. Radiation Oncology  (2016) 11:136 Page 10 of 12
30. Potter BK, Hwang PF, Forsberg JA, Hampton CB, Graybill JC, Peoples GE, et
al. Impact of margin status and local recurrence on soft-tissue sarcoma
outcomes. J Bone Joint Surg Am. 2013;95(20):e151.
31. Sugiura H, Nishida Y, Nakashima H, Yamada Y, Tsukushi S, Yamada K.
Surgical procedures and prognostic factors for local recurrence of soft tissue
sarcomas. J Orthop Sci. 2014;19(1):141–9.
32. Biau DJ, Ferguson PC, Chung P, Griffin AM, Catton CN, O'Sullivan B, et al.
Local recurrence of localized soft tissue sarcoma: a new look at old
predictors. Cancer. 2012;118(23):5867–77.
33. Dickinson IC, Whitwell DJ, Battistuta D, Thompson B, Strobel N, Duggal A, et
al. Surgical margin and its influence on survival in soft tissue sarcoma. ANZ
J Surg. 2006;76(3):104–9.
34. Lewis JJ, Leung D, Heslin M, Woodruff JM, Brennan MF. Association of local
recurrence with subsequent survival in extremity soft tissue sarcoma. J Clin
Oncol. 1997;15(2):646–52.
35. Sabolch A, Feng M, Griffith K, Rzasa C, Gadzala L, Feng F, et al. Risk factors
for local recurrence and metastasis in soft tissue sarcomas of the extremity.
Am J Clin Oncol. 2012;35(2):151–7.
36. Gronchi A, Lo Vullo S, Colombo C, Collini P, Stacchiotti S, Mariani L, et al.
Extremity soft tissue sarcoma in a series of patients treated at a single
institution: local control directly impacts survival. Ann Surg.
2010;251(3):506–11.
37. Zagars GK, Ballo MT, Pisters PW, Pollock RE, Patel SR, Benjamin RS.
Surgical margins and reresection in the management of patients with
soft tissue sarcoma using conservative surgery and radiation therapy.
Cancer. 2003;97(10):2544–53.
38. Kikuta K, Kubota D, Yoshida A, Suzuki Y, Morioka H, Toyama Y, et al. An
analysis of factors related to recurrence of myxofibrosarcoma. Jpn J Clin
Oncol. 2013;43(11):1093–104.
39. Novais EN, Demiralp B, Alderete J, Larson MC, Rose PS, Sim FH. Do
surgical margin and local recurrence influence survival in soft tissue
sarcomas? Clin Orthop Relat Res. 2010;468(11):3003–11. Pubmed Central
PMCID: 2947688.
40. Ipach I, Wingert T, Kunze B, Kluba T. Oncological outcome and prognostic
factors in the therapy of soft tissue sarcoma of the extremities. Orthop Rev
(Pavia). 2012;4(4):e34. Pubmed Central PMCID: 3626305.
41. Liu CY, Yen CC, Chen WM, Chen TH, Chen PC, Wu HT, et al. Soft tissue
sarcoma of extremities: the prognostic significance of adequate surgical
margins in primary operation and reoperation after recurrence. Ann Surg
Oncol. 2010;17(8):2102–11.
42. Catton C, Rumble RB, Warde P, members of the IMRT Indications Expert
Panel. The role of IMRT in soft-tissue sarcomas. 2010.
43. Society AC. Sarcoma: adult soft tissue cancer. 2013.
44. Bagaria SP, Ashman JB, Daugherty LC, Gray RJ, Wasif N. Compliance with
National Comprehensive Cancer Network guidelines in the use of radiation
therapy for extremity and superficial trunk soft tissue sarcoma in the United
States. J Surg Oncol. 2014;109(7):633–8.
45. Leibel SA, Fuks Z, Zelefsky MJ, Wolden SL, Rosenzweig KE, Alektiar KM, et al.
Intensity-modulated radiotherapy. Cancer J. 2002;8(2):164–76.
Epub 2002/05/15.
46. De Neve W, De Gersem W, Madani I. Rational use of intensity-modulated
radiation therapy: the importance of clinical outcome. Semin Radiat Oncol.
2012;22(1):40–9.
47. O'Sullivan B, Griffin AM, Dickie CI, Sharpe MB, Chung PW, Catton CN, et al.
Phase 2 study of preoperative image-guided intensity-modulated radiation
therapy to reduce wound and combined modality morbidities in lower
extremity soft tissue sarcoma. Cancer. 2013;119(10):1878–84.
48. Wang J, Shu-lian W, Yong-wen S, Xin-fan L, Jing J, Wei-hu W, et al.
Postoperative intensity modulated radiation therapy provided favorable
local control in patients with soft tissue sarcoma of extremities and trunk.
Int J Radiat Oncol Biol Phys. 2013;87(2):S64–5.
49. Folkert MR, Singer S, Brennan MF, Kuk D, Qin LX, Kobayashi WK, et al.
Comparison of local recurrence with conventional and intensity-modulated
radiation therapy for primary soft-tissue sarcomas of the extremity. J Clin
Oncol. 2014;32(29):3236–41. Pubmed Central PMCID: 4178522.
50. Wang D, Bosch W, Roberge D, Finkelstein SE, Petersen I, Haddock M, et al.
RTOG sarcoma radiation oncologists reach consensus on gross tumor
volume and clinical target volume on computed tomographic images for
preoperative radiotherapy of primary soft tissue sarcoma of extremity in
Radiation Therapy Oncology Group studies. Int J Radiat Oncol Biol Phys.
2011;81(4):e525–8. Pubmed Central PMCID: 3205346.
51. Haas RL, Delaney TF, O'Sullivan B, Keus RB, Le Pechoux C, Olmi P, et al.
Radiotherapy for management of extremity soft tissue sarcomas: why,
when, and where? Int J Radiat Oncol Biol Phys. 2012;84(3):572–80.
52. Wang D, Bosch W, Kirsch DG, Al Lozi R, El Naqa I, Roberge D, et al. Variation
in the gross tumor volume and clinical target volume for preoperative
radiotherapy of primary large high-grade soft tissue sarcoma of the
extremity among RTOG sarcoma radiation oncologists. Int J Radiat Oncol
Biol Phys. 2011;81(5):e775–80. Pubmed Central PMCID: 3099246.
53. Call JA, Stafford SL, Petersen IA, Haddock MG. Use of intraoperative
radiotherapy for upper-extremity soft-tissue sarcomas: analysis of disease
outcomes and toxicity. Am J Clin Oncol. 2014;37(1):81–5.
54. Nag S, Shasha D, Janjan N, Petersen I, Zaider M, American Brachytherapy
Society. The American Brachytherapy Society recommendations for
brachytherapy of soft tissue sarcomas. Int J Radiat Oncol Biol Phys. 2001;
49(4):1033–43. Epub 2001/03/10.
55. Skowronek J, Piotrowski T. Pulsed dose rate brachytherapy: a method
description and review of clinical application. Przegl Lek. 2002;59(1):31–6.
Brachyterapia nowotworow metoda Pulsed Dose Rate–opis metody oraz
przeglad wskazan do leczenia.
56. Alektiar KM, Leung D, Zelefsky MJ, Healey JH, Brennan MF. Adjuvant
brachytherapy for primary high-grade soft tissue sarcoma of the extremity.
Ann Surg Oncol. 2002;9(1):48–56. Epub 2002/02/07.
57. Pellizzon AC. Evidence and clinical outcomes of adult soft tissue sarcomas
of the extremities treated with adjuvant high-dose-rate brachytherapy - a
literature review. J Contemp Brachytherapy. 2014;6(3):318–22. Pubmed
Central PMCID: 4200188.
58. Kamada T, Tsujii H, Blakely EA, Debus J, De Neve W, Durante M, et al.
Carbon ion radiotherapy in Japan: an assessment of 20 years of clinical
experience. Lancet Oncol. 2015;16(2):e93–e100.
59. O'Sullivan B, Davis AM, Turcotte R, Bell R, Catton C, Chabot P, et al.
Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the
limbs: a randomised trial. Lancet. 2002;359(9325):2235–41. Epub 2002/07/10.
60. Nielsen OS, Cummings B, O'Sullivan B, Catton C, Bell RS, Fornasier VL.
Preoperative and postoperative irradiation of soft tissue sarcomas: effect of
radiation field size. Int J Radiat Oncol Biol Phys. 1991;21(6):1595–9. Epub
1991/11/01.
61. Tseng JF, Ballo MT, Langstein HN, Wayne JD, Cormier JN, Hunt KK, et al. The
effect of preoperative radiotherapy and reconstructive surgery on wound
complications after resection of extremity soft-tissue sarcomas. Ann Surg
Oncol. 2006;13(9):1209–15. Epub 2006/09/05.
62. Davis AM, O'Sullivan B, Bell RS, Turcotte R, Catton CN, Wunder JS, et al.
Function and health status outcomes in a randomized trial comparing
preoperative and postoperative radiotherapy in extremity soft tissue
sarcoma. J Clin Oncol. 2002;20(22):4472–7. Epub 2002/11/15.
63. Sadoski C, Suit HD, Rosenberg A, Mankin H, Efird J. Preoperative radiation,
surgical margins, and local control of extremity sarcomas of soft tissues. J
Surg Oncol. 1993;52(4):223–30. Epub 1993/04/01.
64. Al Yami A, Griffin AM, Ferguson PC, Catton CN, Chung PW, Bell RS, et al.
Positive surgical margins in soft tissue sarcoma treated with preoperative
radiation: is a postoperative boost necessary? Int J Radiat Oncol Biol Phys.
2010;77(4):1191–7.
65. Alamanda VK, Song Y, Shinohara E, Schwartz HS, Holt GE. Postoperative
radiation boost does not improve local recurrence rates in extremity soft
tissue sarcomas. J Med Imaging Radiat Oncol. 2014;58(5):633–40.
66. Davis AM, O'Sullivan B, Turcotte R, Bell R, Catton C, Chabot P, et al. Late
radiation morbidity following randomization to preoperative versus
postoperative radiotherapy in extremity soft tissue sarcoma. Radiother
Oncol. 2005;75(1):48–53. Epub 2005/06/11.
67. Alektiar KM, Velasco J, Zelefsky MJ, Woodruff JM, Lewis JJ, Brennan MF.
Adjuvant radiotherapy for margin-positive high-grade soft tissue sarcoma of
the extremity. Int J Radiat Oncol Biol Phys. 2000;48(4):1051–8. Epub 2000/11/10.
68. Jebsen NL, Trovik CS, Bauer HC, Rydholm A, Monge OR, Hall KS, et al.
Radiotherapy to improve local control regardless of surgical margin and
malignancy grade in extremity and trunk wall soft tissue sarcoma: a
Scandinavian sarcoma group study. Int J Radiat Oncol Biol Phys. 2008;71(4):
1196–203.
69. Ballo MT, Zagars GK, Cormier JN, Hunt KK, Feig BW, Patel SR, Pisters PW.
Interval between surgery and radiotherapy: Effect on local control of soft
tissue sarcoma. Int J Radiat Oncol Biol Phys. 2004;58(5):1461–7.
70. Sampath S, Schultheiss TE, Hitchcock YJ, Randall RL, Shrieve DC, Wong JY.
Preoperative versus postoperative radiotherapy in soft-tissue sarcoma: multi-
Hoefkens et al. Radiation Oncology  (2016) 11:136 Page 11 of 12
institutional analysis of 821 patients. Int J Radiat Oncol Biol Phys. 2011;81(2):
498–505.
71. Cheng EY, Dusenbery KE, Winters MR, Thompson RC. Soft tissue sarcomas:
preoperative versus postoperative radiotherapy. J Surg Oncol. 1996;61(2):90–9.
72. Zagars GK, Ballo MT, Pisters PW, Pollock RE, Patel SR, Benjamin RS.
Preoperative vs. postoperative radiation therapy for soft tissue sarcoma: a
retrospective comparative evaluation of disease outcome. Int J Radiat Oncol
Biol Phys. 2003;56(2):482–8.
73. Guadagnolo BA, Zagars GK, Ballo MT, Patel SR, Lewis VO, Pisters PW, et al.
Long-term outcomes for synovial sarcoma treated with conservation
surgery and radiotherapy. Int J Radiat Oncol Biol Phys. 2007;69(4):1173–80.
74. Greene FL, Compton CC, Fritz AG, Shah JP, Winchester DP. AJCC cancer
staging atlas. 7th ed. 2006.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Hoefkens et al. Radiation Oncology  (2016) 11:136 Page 12 of 12
